申请人:Merck Sharp & Dohme Corp.
公开号:US10450309B2
公开(公告)日:2019-10-22
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B4 receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene B4 receptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.
结构式(I)的新型化合物及其药学上可接受的盐类是白三烯B4受体1(BLT1)的拮抗剂,可用于治疗、预防和抑制由白三烯B4受体1(BLT1)介导的疾病。本发明的化合物可用于治疗 2 型糖尿病、胰岛素抵抗、高血糖、血脂异常、脂质紊乱、肥胖、高血压、非酒精性脂肪肝/非酒精性脂肪性肝炎、代谢综合征、动脉粥样硬化和癌症。